Cited in:


This article has been cited by:

  1. 1
    Z. Shaikhibrahim, A. Offermann, M. Braun, R. Menon, I. Syring, M. Nowak, R. Halbach, W. Vogel, C. Ruiz, T. Zellweger, C. A. Rentsch, M. Svensson, O. Andren, L. Bubendorf, S. Biskup, S. Duensing, J. Kirfel, S. Perner, MED12 overexpression is a frequent event in castration-resistant prostate cancer, Endocrine Related Cancer, 2014, 21, 4, 663


  2. 2
    Dimo Dietrich, Sebastian Meller, Barbara Uhl, Bernhard Ralla, Carsten Stephan, Klaus Jung, Jörg Ellinger, Glen Kristiansen, Nucleic acid-based tissue biomarkers of urologic malignancies*, Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 4, 173


  3. 3
    Christopher E Barbieri, Andrea Sboner, Mark A Rubin, Levi A Garraway, Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453–456, The Journal of Pathology, 2013, 231, 2